Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
With
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic confirmation of locally advanced or metastatic RCC with a clear-cell component with or without sarcomatoid features.
Must not have received any prior systemic therapy for their mRCC.
Measurable disease based on RECIST v1.1.
Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion as required.
Karnofsky performance status ≥ 70%.
Adequate organ function per protocol-defined criteria.
You may not be if
Use of protocol-defined prior/concomitant therapy.
Currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.
History of severe hypersensitivity reaction to study treatments or their excipients.
Active autoimmune disease that has required systemic treatment in past 2 years.
Known additional malignancy that has progressed or has required active treatment in the last 3 years.
Known active central nervous system metastases and/or carcinomatous meningitis.
History of (noninfectious) pneumonitis that required steroids or current pneumonitis.
History or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful.
Significant cardiac event within 12 months before Cycle 1 Day 1.
